Avadomide clinical trials
Also written CC-122.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses avadomide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 1
Celgene (12) · Bristol-Myers Squibb (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test avadomide.
- Nov 2026A Rollover Study of CC-122Phase 1 · Bristol-Myers Squibb
Studies
Open first, then newest update. How each study uses avadomide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Rollover Study of CC-122Active, not recruitingPhase 1Bristol-Myers SquibbNCT05688475Written as CC-122
- A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)TerminatedPhase 1CelgeneNCT02509039Written as CC-122
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedPhase 1CelgeneNCT02031419Written as CC-122
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedPhase 1CelgeneNCT01421524Written as CC-122
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedPhase 1CelgeneNCT02417285Written as CC-122
- Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT03834623Written as CC-122
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedPhase 1/2CelgeneNCT02406742Written as CC-122
- A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)CompletedPhase 1/2CelgeneNCT02859324Written as CC-122
- Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk FactorsCompletedPhase 1CelgeneNCT03283202Written as Avadomide (CC-122)
- Radiolabeled Study of CC-122 in Healthy SubjectsCompletedPhase 1CelgeneNCT02234999Written as CC-122
- Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect StudyCompletedPhase 1CelgeneNCT02049528Written as CC-122
- Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122CompletedPhase 1CelgeneNCT03340662Written as CC-122
- A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal ImpairmentCompletedPhase 1CelgeneNCT03097016Written as CC-122
- Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver CancerTerminatedPhase 1CelgeneNCT02323906Written as CC-122
Given beside what is tested · 1 — avadomide is usual care or a partner of the new treatment
Codes
What other systems call avadomide · ClinicalTrials.gg INT000334
- UNII (FDA) 28DZS29F59AVADOMIDEConfirmed FDA, Wikidata
- Wikidata Q105334256avadomideConfirmed FDA, Wikidata
- NCI Thesaurus C160786AvadomideOne source FDA
- DrugBank DB14857One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 28DZS29F59 | AVADOMIDE | Confirmed FDA, Wikidata |
| Wikidata | Q105334256 | avadomide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C160786 | Avadomide | One source FDA |
| DrugBank | DB14857 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.